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Objective: To find out if the failure in immunotolerance of myasthenia gravis (MG) is a 
possible aspect of deduction in Breg cells and to characterize B cell subsets in MG.
Methods: Flow cytometry detection and enzyme-linked immunosorbent assays in periph-
eral blood films of 10 MG patients and 10 healthy controls (HCs) were performed after 
isolation of B cells. The CD19+CD5+CD1d+ Breg cells percentages were measured to com-
plement a B cell phenotype assay and frequencies of B cell subsets. The clinical outcome 
measures and immunological variables of patients with MG were compared with HCs.
results: Patients with MG had relatively lowered percentages of CD19+CD5+CD1d+ 
Breg cells as compared to HCs. The production of interleukin (IL)-10 and transforming 
growth factor (TGF)-β1 was relatively lesser in patients with MG than HCs, which were 
linked with more severe of MG disease status according to Myasthenia Gravis Foundation 
of America (MGFA) clinical classification. The reduction of cytokine production was more 
significant for IL-10 than TGF-β1 when compared to HCs.
conclusion: It has been observed that the reduced number of B cells is able to produce 
IL-10 in MG patients but lesser than compared to HCs. The Bregs reduction mainly was 
regarded by the severity of disease status, which was highly significant and also by dis-
ease duration which was statistically significant as well. The findings of the measurement 
of B cell phenotype assay and frequencies of B cell subsets between MGs and HCs give 
us new ideas to develop B cell-mediated therapies of MG such as (1) isolated B cells of 
MGs could be cultured with steroids, e.g., dexamethasone in vitro to see if it induces the 
CD19+CD5+CD1d+ Breg cells, (2) it may observe whether induced CD19+CD5+CD1d+ 
Bregs have higher production of IL-10 and TGF-β1, as both are linked with disease 
severity, and (3) after completion in vitro steps, through further research in vivo to observe 
whether it improves the function of MG disease status.
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inTrODUcTiOn
In most cases of myasthenia gravis (MG), myasthenia results from free-flowing antibodies of blood-
stream, which obstructs acetylcholine receptors (AChRs) at the postsynaptic myoneural junction (1). 
Almost 85% MG patients have free-flowing anti-AChR antibodies (2). Muscle-specific tyrosine kinase 
(MuSK) autoantibodies (3, 4) are identifiable in 38–47% MG patients those do not possess identifiable 
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antibody to AChR (3, 5, 6). In the course of immune reaction B 
cells actively shows positive and negative regulatory effects (7). 
They positively modulate immune reaction by creating antigen-
specific antibody and influencing optimal T cell activation (8, 9). 
Moreover, they negatively modulate immune reaction by immune 
modulatory cytokines production, which is described in different 
ranges of mouse models (7, 10–20) are now well established (7, 
14, 21). B cells modulatory function in autoimmune diseases was 
proclaimed by Janeway and colleagues in EAE (17, 22). Bregs 
presence was subsequently supported by other investigators (13, 
22, 23), which shows as of T cell, B cell subsets are also able to influ-
ence immunotolerance (7, 21, 22, 24–27). One of the Bregs subsets 
interleukin (IL)-10 producing B cells (B10 cells) is predominantly 
found within a phenotypically unique CD1dhiCD5+CD19+ subset 
(13, 18, 21, 22, 28). The prevalence and characterization of B10 
cells that are described in autoimmune and inflammatory diseases 
involving rheumatoid arthritis (RA), Graves’ disease, and systemic 
lupus erythematosus (SLE) (29–33). Significantly many studies 
show that Bregs express decreased and deteriorated charac-
terization (29, 32, 33). Anyhow, B cell subpopulation has not been 
characterized in MG patients (32). In this research investigation, 
the presence and dynamics of Breg cells in patients with MG is 
compared with healthy controls (HCs).
Bregs: iTs DeVelOPMenT 
anD FUncTiOn
Bregs are those immunosuppressive cells that support immuno-
logical tolerance. In these recent years, multiple studies in both 
mice and humans have established that Bregs suppress inflam-
matory responses primarily via the provision of IL-10 (14). These 
cells regulate the immune system by various mechanisms. The 
main mechanism is through the production of IL-10, IL-35, 
and transforming growth factor (TGF)-β1 (34). It is thought 
that Bregs arise from a common progenitor T2-MZP B cells. 
These T2-MZP B cells are at an immature point of develop-
ment and are thought to be autoreactive after interacting with 
environmental triggers. After T2-MZPs are activated by toll-like 
receptors on pathogens the first wave of IL-10 is released (14). 
IL-10 has strong anti-inflammatory effects (35), and it inhibits 
or suppresses inflammatory responses mediated by T cells. The 
produced IL-10 by Bregs can repress noxious immune reaction 
through controlling Th1/Th2 stability and through reducing 
intrinsic cell-intervened inflammation (36). Bregs also produce 
another anti-inflammatory cytokine TGF-β (35). Bregs subset 
that is able to produce TGF-β1 in vitro has been determined (37, 
38). TGF-β1-producing Bregs subset participates in the initiation 
of low-dose oral tolerance (38).
aiMs anD OBJecTiVes
To identify the existence of Bregs and characterization of Bregs 
in MG in comparison with HCs. To understand the role of Bregs 
including IL-10 and TGF-β1 secretion in patients with MG in 
comparison with HCs, which may contribute to new B cell-
mediated therapies of MG. CD5+CD19+CD1d+ Breg cells are to 
be characterized by flow cytometry detection of isolated B cells 
and the expression level in both MG patients and HCs are to 
measure. Through an observation with enzyme-linked immuno-
sorbent assay (ELISA), it can be known if the decreased number 
of Bregs is able to produce IL-10 and TGF-β1 in MG patients.
MaTerials anD MeThODs
Materials and equipment
Sample blood; anticoagulant; lymphocyte separation medium 
(LSM); phosphate buffered saline (PBS); buffer; fetal bovine 
serum (FBS); human antibiotic (HuAB); RPMI 1640 medium; 
B cell isolation kit II; human IL-10 and TGF-β1 ELISA kit; 
PerCP-cy™5.5 mouse anti-human CD19; FITC mouse anti-
human CD5; PE mouse anti-human CD1d; clinical centrifuges; 
water bath (37°C); refrigerator; cell culture dishes and flasks; cen-
trifuge tubes; pipettes; hemocytometer; MS column; miniMACS 
separator; standard ELISA microplate reader; and flow cytometer.
standard Protocol approval, registration, 
Patients consent
The study was carried out in accordance with the recommenda-
tion of the Institutional Review Board. This research project was 
approved by the Hubei University of Medicine, Shiyan, Hubei 
442000, China. The research project was specifically reviewed and 
approved by the evaluation committee of the Hubei University of 
Medicine. Informed consent was obtained from all MG patients 
and HCs. Before including, the participants were explained the 
aim of the research project. Once the verbal consent was under-
stood and agreed, a written consent was then gathered from each 
of the participants including their legal identification. Those 
individuals or patients agreed to give the written consent were 
only included in this research project.
study Population and hcs
Patients with MG were involved from Taihe Hospital, Shiyan, 
Hubei 442000, China. Sample blood was obtained from 10 
patients with MG; age between 16 and 58 years. All MG patients 
had detectable anti-AChR/anti-MuSK antibodies at the time 
of diagnosis among which seven MG patients had detectable 
anti-AChR antibodies. Data collection (see Table 1) has taken 
such as disease duration, medications taken (prednisone, 
cyclosporine or mycophenolate mofetil, and so on), or thymec-
tomy status. Blood samples were collected in the morning prior 
taking any medications so that the Bregs were not affected by 
current medications taken, medications doses, and treatment 
duration. So that the drugs did not affect the flow cytometry 
results and the severity of the disease measured by quantitative 
myasthenia gravis (QMG) scoring and MGFA class. Patients 
were having the usual adult doses and continued medication 
when the patient was diagnosed for the first time with MG. The 
QMG scoring was done according to the QMG test manual by 
MGFA (39, 40).
Blood samples from 10 HCs were obtained from those were 
not receiving any treatment for any other autoimmune diseases. 
TaBle 1 | Data collection sheet of myasthenia gravis patients.
sl. no. age (years) sex (M/F) Disease time 
(months)
Meds taken Thymectomy 
status
Myasthenia gravis  
Foundation of america  
(MgFa) class





01 39 F 9 Pyrid Not done Class IIa Class I 4
02 25 F 24 Pred Not done Class IIb Class IIa 13
03 51 F 120 Pyrid + Pred Not done Class IVb Class IIIb 30
04 51 F 36 Cyclo Not done Class IIa Class IIa 16
05 23 F 4 Pyrid Not done Class I Class I 4
06 22 M 10 None Done Class IIIb Class IIb 24
07 27 F 120 MMF Not done Class IVa Class IIIa 26
08 47 M 12 Pyrid + Aza Not done Class IIIa Class IIb 22
09 16 F 12 Pred Not done Class I Class I 5
10 58 M 4 Pyrid Not done Class I Class I 3
Pred, prednisone; Cyclo, cyclosporine; Aza, azathioprine; Pyrid, pyridostigmine; MMF, mycophenolate mofetil.
FigUre 1 | The expression of cD19+cD5+cD1d+ Bregs in healthy 
controls. B cells flow cytometry analysis. (a) Forward scatter (FSC-A) 
measures cell size, and side scatter (SSC-A) measures cell granularity. 
Counting beads (black, red, and green) and B cells gates are depicted.  
(B) B cells gating revealed a CD19+ population (green) and a CD19− 
population (red). (c) CD19+ B cells gating revealed CD5+CDld+ (Q2) 
population. Bregs are defined as CD19+CD5+CDld+.
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HCs were matched to the patients with regard to the age, gender, 
and weight.
isolation and storage of Peripheral Blood 
Mononuclear cells (PBMcs)
Peripheral blood was collected in a 20-ml disposable syringe, 
and anticoagulant was added to the sample blood. The blood 
sample was first diluted in PBS (Goodbio, Wuhan, China) 
gently, then according to the manufacturer’s protocol, PBMCs 
were isolated using LSM (TBD sciences, Tianjin, China) 
and added culture medium (RPMI 1640 Medium  +  10% 
FBS +  1% HuAB) then transferred to the cell culture flask 
using a pipette.
isolation and storage of B cells
The PBMCs were counted using a hemocytometer and determined 
the cell number. It was then isolated using B cell isolation kit II 
(Miltenyi Biotec, Auburn, CA, USA) and MS Columns (Miltenyi 
Biotec, Auburn, CA, USA). Added culture medium (RPMI 1640 
Medium + 10% FBS + 1% HuAB) on the isolated B cells then 
transferred to a cell culture dish using a pipette.
Flow cytometry
After the centrifugation and removal of media, cells were sur-
face stained with PerCP-Cy™5.5 mouse anti-human CD19; PE 
mouse anti-human CD1d; and FITC mouse anti-human CD5 
(BD Biosciences, San Diego, CA, USA). After 30 min of incuba-
tion in a refrigerator at 4°C, cell suspension was resuspended in 
PBS and it was then ready for the flow cytometry detection. The 
samples were read by “BD FACSCantoTM II” flow cytometer (BD 
Biosciences, San Jose, CA, USA), and data were analyzed by “BD 
FACSDivaTM V7.0” software (see Figures 1 and 2).
enzyme-linked immunosorbent assay
Human IL-10 and human TGF-β1 ELISAs were performed 
using the human IL-10 ELISA kit and human TGF-β1 ELISA 
kit (NeoBioscience, Shenzhen, China) according to the manu-
facturer’s protocols. Absorbency was measured using a standard 
ELISA microplate reader (Thermo Fisher Scientific, Vantaa, 
Finland). Unused reagents after the experiment are completed, 
stored back in a refrigerator to restore temperature.
Data analysis and statistics
Data are shown as (means ± SD) and analyzed by “SPSS V22.0.” 
The Student’s two-tailed t-test was done to identify significant 
differences between sample means. P  <  0.05 was considered 
statistically significant.
FigUre 2 | The expression of cD19+cD5+cD1d+ Bregs in myasthenia 
gravis patients. B cells flow cytometry analysis. (a) Forward scatter (FSC-A) 
measures cell size, and side scatter (SSC-A) measures cell granularity. 
Counting beads (black, red, and green) and B cells gates are depicted.  
(B) B cells gating revealed a CD19+ population (green) and a CD19− 
population (red). (c) CD19+ B cells gating revealed CD5+CDld+ (Q2) 
population. Bregs are defined as CD19+CD5+CDld+.
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resUlTs anD OBserVaTiOn
Flow cytometry Detection
Bregs Expression in MG and HCs
Reduced CD19+CD5+CD1d+ Bregs expression significantly in B 
cells of patients with MG (n = 10, 19.09 ± 2.61%) as compared to 
HCs (n = 10, 31.42 ± 5.55%) (P = 0.001).
enzyme-linked immunosorbent assay
IL-10 Secretion in MG and HCs
Reduced IL-10 secretion significantly in B cells of patients with 
MG (n = 10, 0.20 ± 0.04) as compared to HCs (n = 10, 0.51 ± 0.09) 
(P = 0.001).
TGF-β1 Secretion in MG and HCs
Reduced TGF-β1 secretion significantly in B cells of patients with 
MG (n = 10, 0.56 ± 0.14) as compared to HC (n = 10, 0.95 ± 0.47) 
(P = 0.031).
Overall results
Clinical outcome measures as per data collection (see Table 1), 
such as disease duration, medications were taken or thymectomy 
status of each patient. The reduction of CD19+CD5+CD1d+ Bregs 
was not affected by current medications taken as all the samples 
were collected in the morning and right before thymectomy was 
done. We have found that the correlation between the reduc-
tion of CD19+CD5+CD1d+ Bregs and severity of the disease 
status is highly significant as the reduction was more in severe 
patients as per MGFA clinical classification, as measured by 
QMG scores (r = −0.844; P = 0.002) (Figure 3A). We also have 
observed a statistically significant correlation between reduction 
of CD19+CD5+CD1d+ Bregs and disease duration (r = −0.656; 
P = 0.040) (Figure 3B).
DiscUssiOns
In this research, we have established that a subset Bregs is related 
to the pathologic process of MG patients. The expression of 
CD19+CD5+CD1d+ Breg cells is reduced significantly in patients 
with MG (19.09 ± 2.61%) as compared to HCs (31.42 ± 5.55%) 
(P = 0.001). These deductions can be secondary to the pathologi-
cal process of MG or a primary cause that leads to the initiation of 
autoreactive T and B cells. In order to distinguish the concept and 
apply the operational interpretation of Bregs in MG in addition 
to finding out the content in vitro expansion and suppression of 
effector T, B, and antigen-presenting cells, their antigen specific-
ity and presence or absence in thymus abnormality tests could be 
conducted (32).
Furthermore, studies have found that the idea of Bregs has 
been greatly related with IL-10 productivity and hinted that a 
comparative study may be done among MG patients and HCs 
so that the expression of the B10 cells like IL-10 expression 
may be analyzed. The decreased secretion of IL-10 in MG 
may be consequential to the pathologic process of MG, and 
the aftereffect of these studies could contribute to an effec-
tive treatment progress of MG patients (19). So, through the 
ELISAs of human, IL-10 has been institutionalized here that 
the B cells are capable of producing both IL-10 in patients with 
MG (0.20 ± 0.04) but lesser as compared to HCs (0.51 ± 0.09) 
(P = 0.001). There has been a wide debate about the identifica-
tion of Bregs and the role of IL-10 in autoimmune diseases. The 
CD5+CD1d+ Bregs identified in our study may be a minuscule 
subset of a larger population of IL-10 producing B cells or B10 
cells, which as a whole are only identifiable by their capability 
to express IL-10.
In a previous study, the production of IL-10 was found to be 
higher in RA, primary Sjogren’s syndrome (SjS) and SLE pointing 
to B cell hyperactivity as the cause of these autoimmune diseases 
(41). In vivo dysregulation of IL-10 gene expression was studied 
in patients with RA, primary SjS, and SLE. Voluntary IL-10 
production by PBMCs was measured by reverse transcription-
polymerase chain reaction and ELISA in untreated patients 
with these diseases and in HCs. It had been found that the IL-10 
production was dramatically higher in RA, primary SjS, and SLE 
patients than in HCs that could play a role in B cell extreme activ-
ity and in the progression of autoimmunity (42).
In SLE patients, a subset of Bregs defined as CD19+CD24hiCD38hi 
with lesser IL-10 secretion and reduced suppressive function 
when matched with HCs. Nevertheless, recombinant IL-10 has 
been proposed as a therapeutic treatment for RA due to its effi-
cacy in the mouse model collagen-induced arthritis (41).
Likewise, in this research, through the ELISAs of human, 
TGF-β1 has been found that the B cells are capable of produc-
ing both TGF-β1 in patients with MG (0.56 ±  0.14) but lesser 
FigUre 3 | (a) Highly significant correlation between CD19+CD5+CD1d+ Bregs reduction in severe myasthenia gravis (MG) patients, as measured by quantitative 
myasthenia gravis scores (r = −0.844; P = 0.002); (B) statistically significant correlation between CD19+CD5+CD1d+ Bregs reduction and disease duration shown in 
months (r = −0.656; P = 0.040). (Note: Bregs were not affected by current medications taken, medications doses, and treatment duration as all the samples were 
collected in the morning before having medication and right before thymectomy was done. Patients were having the usual adult doses and continued medication 
when the patient was diagnosed for the first time with MG.).
TaBle 2 | cD19+cD5+cD1d+ Bregs expression and interleukin (il)-10 
and transforming growth factor (TgF)-β1 secretion in isolated B cells in 
patients with myasthenia gravis (Mg) (n = 10) as compared to healthy 
controls (hcs) (n = 10).
group Bregs (%) il-10 (pg/ml) TgF-β1 (pg/ml)
MG 19.09 (±2.61) 0.20 (±0.04) 0.56 (±0.14)
HC 31.42 (±5.55) 0.51 (±0.09) 0.95 (±0.47)
Mean (±SD).
CD19+CD5+CD1d+ Bregs expression and IL-10 and TGF-β1 secretion differ from MG 
with HCs.
P < 0.05 (compared with HCs, CD19+CD5+CD1d+ Bregs expression and IL-10 and 
TGF-β1 secretion in MG are significantly lower).
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as compared to HCs (0.95 ± 0.47) (P = 0.031). So, it has been 
observed that in patients with MG the CD19+CD5+CD1d+ Bregs 
are not only reduced in number as well as reductions in function 
by decreasing in cytokine production, e.g., IL-10 and TGF-β1. 
In this research, it has been also being noticed that the reduced 
number of cytokine production also differs from each other 
when to compare to HCs, e.g., IL-10 of MG is compared to HCs 
(P =  0.001); TGF-β1 of MG is compared to HCs (P =  0.031). 
It means the reduction of cytokine production in MG is more 
significant for IL-10 than TGF-β1, which also shows that the 
primary concern when further research on inducing cytokine 
production should be on IL-10, as reduced IL-10 production on 
MG is more significant than TGF-β1.
The study findings of the identification of the existence of 
Bregs and the significant reduction of the number of Bregs in MG 
as compared to HCs; the reduction of IL-10 and TGF-β1 secretion 
in patients with MG as compared to HC in this research could 
contribute to new B cell-mediated therapeutic strategies in future. 
If the CD19+CD5+CD1d+ Bregs in cell culture of MG patients 
could be induced whether to follow it may improve the function 
of MG disease status.
cOnclUsiOn
In this research project, flow cytometry detection and ELISAs 
in peripheral blood films of 10 MG patients and 10 HCs were 
performed after isolation of B cells using B cell isolation kit II 
and MS column. The expression of CD19+CD5+CD1d+ Bregs 
was significantly decreased in patients with MG as compared to 
HC (P = 0.001). The IL-10 secretion was significantly reduced in 
patients with MG (P = 0.001); TGF-β1 secretion was also signifi-
cantly reduced in patients with MG (P = 0.031) as compared to 
HC (see Table 2). From this research, it has been observed that 
the reduced number of B cells is able to produce IL-10 in MG 
patients but lesser than compared to HCs. Also, the reduction of 
Bregs in MG was significantly more with greater severity of the 
MG disease status according to the MGFA clinical classification. 
In addition, disease duration also had an effect on reduction of 
Bregs in MG but not as much as the severity of the disease.
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